Thank you for Subscribing to Med Tech Business Review Weekly Brief
Medtech Business Review | Wednesday, April 15, 2026
Continuous glucose monitoring has moved beyond a specialist tool for insulin-dependent patients into a broader instrument for early intervention, behavioural insight and long-term metabolic management. Across Europe, a significant proportion of individuals in early-stage type 2 diabetes remain outside structured monitoring frameworks, limiting the ability of clinicians to influence progression through timely, data-informed decisions. This gap has shifted attention toward systems that extend access without compromising clinical reliability.
Adoption challenges tend to emerge from three intersecting pressures. Device economics and sustainability increasingly influence procurement decisions, particularly in public health systems where long-term cost and environmental impact are scrutinised alongside clinical value. Traditional CGM models, often reliant on frequent sensor replacement and disposable components, introduce recurring costs and waste that scale quickly across large patient populations. Decision-makers now prioritise solutions that reduce lifecycle burden while maintaining consistent performance.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Clinical confidence remains another decisive factor. Monitoring systems must demonstrate not only accuracy against established glucose measurement standards but also stability across varied patient conditions and wear scenarios. Real-world consistency, rather than controlled trial performance alone, determines whether clinicians can rely on data for treatment adjustments. Systems that support reproducibility across placement sites and maintain low variability in readings strengthen their role in guiding therapeutic decisions, particularly in patients with multiple comorbidities or fluctuating glycaemic profiles.
User engagement completes the equation. Passive data collection offers limited value if patients do not translate insights into daily behavioural changes. Effective systems encourage active interaction by presenting data in a way that is both immediate and actionable, allowing users to connect lifestyle choices with measurable outcomes. Frequent data capture, intuitive interfaces and timely alerts contribute to sustained adherence, which in turn reinforces clinical effectiveness. High completion rates of sensor wear cycles often signal that a system has successfully aligned usability with patient routines.
Against this backdrop, Anytime CT3 presents a model that aligns closely with these evolving expectations. Its approach centres on extending access to continuous monitoring earlier in the diabetes journey while addressing practical constraints that have historically limited adoption. The rechargeable transmitter design, capable of extended use over multiple years, directly reduces waste and recurring replacement costs, supporting both economic and environmental considerations at scale. Clinical validation demonstrates strong alignment with traditional glucose measurement methods, while real-world studies indicate sustained time within target glucose ranges and low variability, even among complex patient groups.
The system’s emphasis on usability is evident in high rates of independent sensor application and consistently positive user feedback, indicating that design simplicity translates into adherence. Continuous data capture paired with real-time feedback enables users to interpret glucose trends in relation to daily activities, encouraging proactive management rather than episodic checking. Integration with broader digital health ecosystems and support for remote monitoring further positions it within contemporary care models, where data continuity across platforms is essential.
Anytime CT3’s standing within established healthcare frameworks, including its presence in structured procurement pathways, reinforces its credibility for institutional adoption. Its combination of sustained device performance, accessible design and integration capability reflects a solution calibrated not only for individual patient benefit but also for system-wide scalability, making it a compelling choice for organisations aiming to expand continuous glucose monitoring into earlier stages of care.
More in News